Clinical trial of paliperidone extended-release tablets in the treatment of schizophrenia
10.13699/j.cnki.1001-6821.2018.07.015
- VernacularTitle:帕利哌酮缓释片治疗精神分裂症的临床研究
- Author:
Jin-Cheng WANG
1
;
Chao-Min WANG
;
Yi-Ran GE
;
Hong GUO
;
Bo XIN
;
Xiao-Chuan ZHAO
;
Mei SONG
Author Information
1. 河北医科大学第一医院精神科/河北医科大学精神卫生研究所/河北省脑老化与认知神经科学重点实验室
- Keywords:
paliperidone extended release tablet;
olanzapine tablet;
schizophrenia;
safety
- From:
The Chinese Journal of Clinical Pharmacology
2018;34(7):786-789
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the clinical efficacy and safety of paliperidone extended-release tablets in the treatment of schizophrenia.Methods Thirty patients with schizophrenia were randomly divided into control group and treatment group with 15 cases per group.Control group was given olanzapine with the initial dose of 10 mg and the maximum dose of 20 mg,bid,orally.Treatment group was given paliperidone sustained-release tablets 3 mg,qd,orally,and according to the patients' symptoms,the dose was increased at the speed of 3 mg · d-1,also the maximum dose was 12 mg.Two groups were treated for 8 weeks.The clinical efficacy,myocardial enzymes,executive function and adverse drug reactions were compared between the two groups.Results After treatment,the total effective rates of the treatment and control groups were 93.33％ (14 cases/15 cases) and (9 cases/15 cases) with significant difference (P ＜ 0.05).After treatment,the main indexes in treatment and control groups were compared:alkaline phosphatase were (72.51 ±8.82) and (83.24 ±9.15) U · L-1,alpha hydroxybutyrate dehydrogenase were (128.66 ± 15.42) and (142.13 ± 12.65) U · L-1,creatine kinase were (56.37 ± 8.29) and (62.15 ± 6.45) mmol L-1,lactate dehydrogenase were (51.35 ± 6.37) and (58.32 ± 6.15) mmol · L-1,creatine kinase isoenzyme were (4.15 ± 2.40) and (5.86 ± 0.87) mmol · L-1,wisconsin card sorting test persistent error number were (6.13 ± 0.85) and (5.08 ± 0.68) times,executive function behavior rating scale scores were (66.82 ± 8.46) and (55.68 ± 6.24) points,the differences were statistically significant (all P ＜ 0.05).No adverse drug reactions occurred in the two groups.Conclusion Paliperidone extended-release tablets have a definitive clinical efficacy and safety in the treatment of schizophrenia,which can significantly improve the myocardial function and executive function.
